meRfi®-GM
Gut microbiota & Irinotecan
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Gut microbes also influence drugs that undergo enterohepatic recycling by reversing host enzyme metabolic processes and increasing exposure to toxic metabolites as exemplified by the chemotherapy agent irinotecan and non-steroidal anti-inflammatory drugs
People have different gut bacteria, which can change how they react to drugs. For instance, not everyone experiences the same side effects from the cancer drug [irinotecan](brain://SMOjIU8MpUC00ksfc5CEgA/Irin…
References (Sources)
- Alleviating cancer drug toxicity by inhibiting a bacterial enzyme
- Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic VariabilityReview
- Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats
- Human microbiome signatures of differential colorectal cancer drug metabolism
- Intestinal microflora and digestive toxicity of irinotecan in mice
- Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
- Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea